Status:
COMPLETED
Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma
Lead Sponsor:
Benha University
Conditions:
Pediatric Glaucoma
Eligibility:
All Genders
Up to 12 years
Phase:
EARLY_PHASE1
Brief Summary
To asess the efficacy and safety of combining subconjunctival bevacizumab with mitomycin C (MMC) during AGV revision surgery in pediatric patients with recurrent glaucoma.
Detailed Description
Recurrent pediatric glaucoma following Ahmed Glaucoma Valve (AGV) implantation presents a therapeutic challenge. This study evaluates the efficacy and safety of combining subconjunctival bevacizumab w...
Eligibility Criteria
Inclusion
- children under 12 years with previous AGV implantation for primary congenital glaucoma
Exclusion
- age \>12 years, eyes with no light perception, and those with prior cyclodestructive procedures.
Key Trial Info
Start Date :
February 9 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 15 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06983704
Start Date
February 9 2024
End Date
February 15 2025
Last Update
May 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Azhar University
Cairo, Egypt